Aoxiang Pharmaceuticals (603229.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 71.9313 million yuan, a year-on-year decrease of 65.26%.

Zhitong Finance APP News, Aoxiang Pharmaceutical (603229.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved revenue of 610 million yuan, a year-on-year decrease of 5.53%; net profit attributable to the parent company was 71.9313 million yuan, a year-on-year decrease of 65.26%; net profit after deducting non-recurring gains and losses was 56.1982 million yuan, a year-on-year decrease of 69.33%; basic earnings per share were 0.09 yuan.